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Abstract DNA fragmentation factor is a heterodimer
complex of the nuclease CAD and its speciﬁc inhibitor
ICAD, which can be activated during apoptosis to induce
DNA fragmentation. Although ICAD expression levels
have been quantiﬁed in a variety of human cancer cells, the
mechanism of ICAD gene regulation remains unknown.
In this study, we identiﬁed a 106-bp TATA-less region
upstream of the transcription start site as a basal promoter
of the human ICAD gene. An E-Box motif, which binds
transcription factors of the basic helix-loop-helix/leucine
zipper family, is responsible for transcriptional activity, as
demonstrated using mutated promoter-reporters. A chro-
matin immunoprecipitation assay further demonstrated that
Myc binds to an endogenous ICAD promoter. The func-
tional importance of Myc in the regulation of ICAD
transcription was also demonstrated by knock-down of
c-Myc and N-Myc gene expression, as well as their ectopic
expression. Structural analysis of the human ICAD pro-
moter and identiﬁcation of factors which regulate its
activity might further our understanding of the biological
role of ICAD with respect to regulation of apoptosis and
cancer development.
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Introduction
Apoptosis orprogrammed cell death ensuresthe elimination
of unwanted cells during normal development and homeo-
stasis [1]. This process is progressively inactivated during
malignantdevelopmentandlossofthecapacityforapoptosis
is a hallmark of malignant cells. Chromatin condensation
and internucleasomal DNA fragmentation are typical
nuclear features and well-recognized events in apoptosis.
DNA fragmentation factor (DFF) is a heterodimer protein
composed of a 40-kDa caspase-activated DNase (CAD)
otherwiseknownasDFF40,anditscognate45-kDainhibitor
(inhibitor of CAD: ICAD or DFF45 [2–8]). Both human
genes map to 1p36 [9, 10]. CAD is thought to be responsible
forthemajorityofnuclearactivityresultinginchromosomal
DNA fragmentation. When apoptosis is activated, ICAD is
cleaved by executor caspases, mainly caspase-3, into three
fragments, after which it dissociates from CAD, resulting in
CAD activation.
Thus, the DFF complex may play a role in malignant
transformation, and up- or down-regulation of ICAD/CAD
expression might correlate with cancer aggression. Expres-
sion levels of ICAD have been examined in a variety of
human cancers. For example, ICAD expression is down-
regulated during the exponential growth phase of human
colon carcinoma cells [11]. In some neuroblastomas, pref-
erentialICADexpressionisobservedinlow-stage,butnotin
their high grade [12]. Other research suggests that down-
regulation of ICAD may contribute to tumor growth and
lymph node metastasis in esophageal carcinoma [13], and
that ICAD expression might serve as a marker of aggressive
tumor behavior with an associated poor prognosis inovarian
cancer [14]. We have previously demonstrated that the
hepatitis C virus core protein, which not only encodes the
viral nucleocapsid but has a number of properties enabling
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thereby increasing steady-state levels of the ICAD protein
[15].Todate, themechanismoftranscriptional regulationof
the ICAD gene is not well understood. Analysis of the gene
structure of mouse ICAD showed that a 118-bp ﬂanking
region of the ICAD gene is required for promoter activity
[16]. In this study, we identiﬁed a functional promoter of the
human ICAD gene and investigated the role of c-Myc and
N-Myc in regulation of the ICAD promoter.
Materials and methods
Cell cultures
Human hepatoblastoma cells (Huh-7), human oral squa-
mous carcinoma cells (HSC-2, HSC-3 and Ca22-9), mouse
neuroblastoma cells (IMR-32 and GOTO) and mouse 3T3
cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum, 100 units/ml of penicillin, and 100 mg/ml of
streptomycin and kept at 37C in a 5% CO2 incubator.
Cloning of the 50-upstream region of the human
ICAD gene
Human genomic DNA was isolated from Huh-7 cell lines
using the QIAamp DNA Mini kit according to the manu-
facturer’s instructions (QIAGEN). A 50-upstream region of
the ICAD gene was ampliﬁed by PCR using primers based
on the genomic DNA sequence of the human ICAD gene
(GenBank accession No. NM_004401). Primers containing
EcoRI sites were used as follows: forward (50-GA-
ATTCAGGCTGGTCTCAAACTACTG-30) and reverse
(50-GAATTCGATCTCGCCAGATTCTGGTA-30). The
PCR reaction was carried out at 94C for 1 min, 55C for
1.5 min, and 72C for 2 min, for total of 35 cycles. Each
PCR product was puriﬁed and subcloned into a pGEM-T
Easy vector (Promega), followed by sequencing using an
ABI PRISM 310 automated DNA sequencer (Applied
Biosystems).
50 rapid ampliﬁcation of cDNA ends (50-RACE) assay
The 50 ends of the ICAD transcript were cloned by
50-RACE using a Gene Racer RACE-Ready cDNA kit in
accordance with the manufacturer’s instructions (Invitro-
gen). Double-stranded cDNA molecules prepared from
human liver poly(A)
+ RNAs ligated by exposure to the
adaptor were ampliﬁed in a primary PCR reaction using the
adaptor primer 1 and the ICAD gene-speciﬁc antisense
primer ICA1AS (50-GTGCTGTTCGCGGCTGTAGTT-30,
nt -147 to -173), followed by a secondary PCR reaction
using nested oligonucleotides, the adaptor primer 2, and the
antisense ICAD speciﬁc primer ICA2AS (50-CACGG
TGACTGGTGTCAGGGACTTATC-30,n t-228 to -254).
PCR products were puriﬁed and cloned, followed by
nucleotide sequencing as described above.
Plasmid constructions
The 1-kb sequence containing the human ICAD promoter
was excised by digestion of the above-mentioned pGEM-T
vector with SacI and HindIII, and then cloned into the
ﬁreﬂy-luciferase-expressing reporter plasmid pGL3-Basic
(Promega), resulting in pLUC1005. A series of constructs
with 50 end-deletions of the ICAD promoter were created
by PCR ampliﬁcation using the reverse primer (50-CAA
GCTTGCCTCCACAAGGTGGGACCTG-30) and the fol-
lowing forward primers: 50-GGCTAGCCAGTACCCATTT
CTGAAGAAG-30 (nt -936 to +71), 50-GGCTAGCCCTCA
TTTGGGTCCATTTTCC-30 (nt -622 to +71), 50-GGCTAG
CCAGCTTTTTCAGACAGAATGG-30 (nt -272 to +71),
50-GGCTAGCCAGCTTTTTCAGACAGAATGG-30 (nt -205
to +71), 50-GGCTAGCCAGCTTTTTCAGACAGAATGG-30
(nt -145 to +71), 50-GGCTAGCCAGCTTTTTCAGACA
GAATGG-30 (nt -106 to +71), 50-GGCTAGCCTATTTA
GTTTGGTTAGTAAT-30 (nt -90 to +71), and 50-GGCTAG
CCCAGATGGTAAATATACACAA-30 (nt -43 to +71).
Each SacI/HindIII fragment was inserted into the pGL3-basic
vector to yield pLUC(-936/+71), pLUC(-622/+71),
pLUC(-272/+71), pLUC(-205/+71), pLUC(-145/+71),
pLUC(-106/+71), pLUC(-90/+71) and pLUC(-43/+71).
Transfection and reporter assay
Huh-7 cells were seeded at 5 9 10
4 cells/well in 24-well
plates and maintained at 37C in a 5% CO2/95%
atmosphere. DNA transfection of cells with each ICAD-
promoter-luciferase construct (1 lg) with an internal con-
trol vector pRL-TK (0.1 lg) (Promega) was performed
with Trans IT LT-1 (Mirus) during 6-h of incubation. Cells
were then rinsed with phosphate-buffered saline (PBS)
48 h after transfection, and luciferase activity was mea-
sured in the cell lysate using dual luciferase assay reagents
(Promega) [17]. Fireﬂy luciferase activity was standardized
according to Renilla luciferase activity.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performedusing
the ChIP assay kit (Upstate). Brieﬂy, cells in 100-mm dishes
weregrownto70%conﬂuencyover48 h.Thechromatinfrom
formaldehyde-ﬁxed cells was sonicated and immunoprecipi-
tated using mouse monoclonal anti-c-Myc or anti-N-Myc
antibodies (Santa Cruz). The chromatin immunoprecipitate
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(50-CGAGCTCGGTATACATGCGTGTGCATCG-30)a n d
R1 (50-CAAGCTTGCCTCCACAAGGTGGGACCTG-30)
for amplifying the region from nt -272 to -71 containing
potential Myc-binding sites; and F2 (50-GAGATCAAAAC
TGCAGTGAG-30)a n dR 2( 5 0-CACTGTTGGAGATTGTT
CAG-30) for amplifyingthe regionfrom nt-789to-451that
does not contain Myc-binding sites.
Western blotting
CellswerewashedwithPBSandlysedinSDSsamplebuffer.
Cell lysate samples were separated by 10% SDS-polyacryl-
amide gel electrophoresis and electrotransferred to a
polyvinylidene diﬂuoride membrane (Immobilion;
Millipore). After blocking in nonfat milk solution (Blocking
One; Nakaraitesk), the membranes were probed with mono-
clonal antibody against the ICAD protein (Santa Cruz),
c-Myc (Sigma), or N-Myc (Santa Cruz), as the primary
antibody for 1 h. After being washed, the membranes were
incubated with horseradish peroxidase-conjugated anti-
mouse immunoglobulin as the secondary antibody, followed
by visualization with SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce Biotechnology).
siRNA experiments
siRNAs for human c-Myc, N-Myc and the negative control
were purchased from B-Bridge International. Each siRNA
consisted of three different target sequences as follows:
50-GAGGAGACAUGGUGAACCA-30 50-GAGAAUGUCA
AGAGGCGAA-30, and 50-GAGAAUGUCAAGAGGCGAA
-30 forc-MycsiRNA;50-CGGAGAUGCUGCUUGAGAA-30,
50-CGGAGUUGGUAAAGAAUGA-30,a n d5 0-CAGCAGU
UGCUAAAGAAAA-30 for N-Myc siRNA; and 50-ATCC
GCGCGATAGTACGTA-30,5 0-TTACGCGTAGCGTAAT
ACG-30, and 50-TATTCGCGCGTATAGCGGT-30 for the
negativecontrol.Huh-7cellsweretransfectedwith100 pmol/ml
siRNA using FuGENE6 (Roche) in Opti-MEM I (Invitro-
gen), after which the medium was replaced by standard
DMEM after 6 h of transfection.
RNA preparation and real-time quantitative RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen)
according to the manufacturer’s protocol. First-strand
cDNAs were synthesized using the SuperScriptIII First-
Strand Synthesis kit (Invitrogen) and then used as templates
for real-time PCR. Quantitative PCR was performed using
the ABI Prism 7700 sequence detection system using
Taq-ManGeneExpressionassays(AppliedBiosystems).The
standard curve was created using serially diluted total RNA
obtained from Huh-7 cultures and b-actin was chosen as the
internal standard to control for variability in ampliﬁcation.
Ampliﬁcation was performed at 95C for 10 min, followed
by 40 cycles of ampliﬁcation at 95C for 15 s and 60C for
60 s.
Results and discussion
Localization of transcription start sites of the human
ICAD gene
PreciselocalizationoftranscriptionstartsitesoftheICADgene
was examined in human hepatoma Huh-7 cells by 50-RACE
analysis. A fragment of approximately 100 bp was obtained
(Fig. 1a) and cloned, after which sequencing analysis of sev-
eralcDNAclones identiﬁedtwoof50 termini (Fig. 1b).These
were located 71 and 68 nucleotides upstream from the trans-
lationstartcodonofthe ICADgene.Fromadatabasesearchof
the DBTSS [18], we found that these are two of multiple sites
for putative transcription initiation for the human ICAD gene.
Althoughtranscriptionmaybeinitiatedatbothsites, theupper
site was designated position +1 in this study.
Characterization of the ICAD gene promoter
To examine potential regulatory sequences involved in
ICAD gene expression, a 1 kb 50-upstream region of the
ICAD gene was sequenced and analyzed. The overall GC
content of the 1-kb genomic DNA fragment was 46%,
while GC content among the 200 bp proximal to the ATG
start codon was approximately 62%. A search of tran-
scription consensus motifs using the TRANSFAC database
[19] demonstrated that none of the major eukaryotic pro-
moter elements, TATA-, CCAAT-, or GC box, were
located within 200 bp upstream of the transcription start
site, although a TATA-like element was found more than
400 bp upstream from the start sites, indicating that the
human ICAD gene has a TATA-less promoter. No CpG
island, which is frequently observed in the TATA-less
promoter, was found by screening with the CpG island
searcher (http://cpgislands.usc.edu/). Absence of a TATA-
like sequence upstream of the transcription start site has
also been reported for the mouse ICAD gene, suggesting
that TATA-less promoters might be a common feature in
transcriptional regulation of the ICAD gene.
AsshowninFig. 1b,the1-kbsequencecontainspotential
binding sites for several transcription factors. The ability of
the 50-upstream region of the ICAD gene to function as a
promoterwasassessedbyitscapacitytodrivetheexpression
of a luciferase reporter gene. A series of constructs in which
genomicDNAfragmentswerefusedtoapromoterlessﬁreﬂy
luciferase gene of the pGL3-basic vector were generated
with the 30 end always terminating +71 bp from the
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123transcription start site. The 50 ends began at bases -936,
-662, -272, -205, -145, -106, -90, and -43 (Fig. 2).
Promoter activity was assessed by measuring luciferase
activity in transiently transfected Huh-7 cells. Luciferase
activity was normalized to Renilla luciferase activity. As
showninFig. 2ontheright,theregionextendingfrom-936
to +71 had promoter activity since luciferase activity of the
reporter gene was 45-fold that of the empty vector. A 50
deletion of the promoter sequence to -662(pLuc(-662/
+71)) enhanced promoter activity, and successive removal
of nucleotides from -272 to -106 also enhanced promoter
activity, suggesting the possibility of negative regulatory
elements within the -936/-622 and -272/-106 regions.
When the sequence from -106 to -90 was removed
(pLuc(-90/+71)), promoter activity fell to parallel that of
the pGL3 basic vector. This suggests the presence of a crit-
icalelementintheregionextendingfrom-106to-90,thus,
we have identiﬁed the region 106 bp upstream of the tran-
scription start site as the basal promoter of the human ICAD
gene.
Myc and USF enhance ICAD promoter activity
As indicated in Fig. 1b, a computer-based sequence analysis
revealedthatthe106 bpregioncontainspotentialbindingsites
for GATA-1, deltaE, Myc, and various upstream stimulatory
B
M     1      2
A
-960 AGGCT GGTCTCAAAC TACTGACCTC AGATCATCTG -901
-900 TCCGCCTCGG CCTCCTAAAG TGCTGAGATT ACAGGGGTGA GCCACCGCCC CCGGGGCCCT -841
-840 TGCCCACGTT TTTATAAACA AAATATGAGG TGGGAGGATT GCTTGAGCCC AGGAGATCAA -781
-780 AACTGCAGTG AGCCATCATC GCGCCACTGC ACTCCAGCCT GGGAGACAGA GCGAAACGCT -721
-720 GTCTCAAAAA AAGAAAAAAG AAACAAGGAA GGAAAGTGTC CCCCGAATGA ATAAATATGA -661
-660 GCAGATAATT ACTTCTAGTT TACATAAAAT GCCCTCTTTT AAGAGAGGAA CTTTTTGATC -601
-600 ATTTTTATTA CTATTCTTTT AATCTTAGAT GTTTATTTTT CAGGAGGAAA AAAACAAACT -541
-540 TTTCCATAGT AGCAGTATTA AAACAAAGAT GAATATGTTG TCAAGAGGCA TCTGAACAAT -481
-480 CTCCAACAGT GCCGAGTCGC ATTTCCCCTT TCCTCTCCGA TGCATTTGAG ACTTTAATGC -421
-420 TTACTATATT TATTTAAGCG TTTTGTTCTG AGACCCCAAA CTAATTTGCA CAGTTGAAGC -361
-360 AGGAAATAGA ATGGGTGGAA ACATGCGGGT GTCTGTATTA GCATTATGCA TCTCATATGC -301
-300 GAATAGGAAT GCTCTAAAAA TTCAATACAG TATACATGCG TGTGCATCGT CATGCAAAAT -241
-240 AAGTCTCTAT TGGCCTTATA TTTGAACGCG CGAATGCAGC TCCTAAAAGT TAAAAACAAC -181
-180 TCCTAGGCTG AATCGCGCGA TAGAACGAAA GCGGCTTTAA ACCCAGAGAC TACAGTTTCC -121
-120 GGCATGCTTC GACGCCACAC GTGATTAGCG GCAACTAGAA CTACATTTCC CGGCGTGCCC -61
-60  TGGTCTCACG TGTGATTTGC TGCGGAACGA ACTACATCTC CCGGCAGGCT GCGGAAGGGG -1
+1   GTCGAGTAGA AGGACCGCCG CTCCGGCCTC CCGCGACTTC TCGAAGGTGG GCAGGTCCCA +60
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Fig. 1 (a) Mapping of the
transcription start sites by 50
RACE analysis. Following
nested PCR reaction, a PCR
product of 100-bp was detected
by 1.5% agarose gel
electrophoresis (lane 2). Lane 1:
no template control; lane M:
100-bp DNA ladder marker.
(b) The 50 ﬂanking region of the
human ICAD gene. The
nucleotide sequence is
numbered from the major
transcription site, which is
indicated by an arrow. Putative
binding sites for transcription
factors analyzed by the
TRANSFAC database and
search program were shown
with underlines
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Fig. 2 Human ICAD promoter drives reporter gene expression in
transiently transfected Huh-7 cells. Deletion constructs of the
upstream region of the ICAD gene linked to the ﬁreﬂy luciferase
reporter gene (LUC) are illustrated in the left. Huh-7 cells were
cotransfected with a ﬁreﬂy luciferase reporter and a Renilla luciferase
internal control (pRL-TK). The relative luciferase activity (RLU) was
obtained by normalizing the ﬁreﬂy luciferase activity to the Renilla
luciferase activity, and is expressed as a percentage of RLU of
pLuc(-936/+71). The average values are shown with standard
deviation (SD) (n = 4 per construct)
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123factors (USF). Within this region, there is a canonical E-box
sequence (50-CACGTG-30) located between -103 and -98.
E box motifs are known to bind to transcription factors of the
basic helix-loop-helix/leucine zipper (bHLH LZ) family,
including Myc and USF [20–23]. We examined the potential
role of E-box-binding proteins, Myc and USF, in potentiating
ICAD gene transcription. Myc is bound to a partner protein
Max via a bHLH LZ domain and the Myc-Max heterodimer
activates transcription by binding to an E-box sequence
[24,25].MaxispresentingreateramountsthanMycsincethe
Myctranscriptandproteinhaveshorterhalf-livescomparedto
Max [26, 27]. Therefore, it is highly likely that Myc is the
limiting,regulatedcomponentoftheheterodimer.Toexamine
the potential role of E box binding proteins, Huh-7 cells were
co-transfected with luciferase reporter plasmids and expres-
sion vectors for c-Myc, N-Myc, USF1, and USF2 (Fig. 3a).
Luciferase activity of the -145/+71 promoter construct
increased 2- to 5-fold, and 1.5- to 2-fold, when co-expressed
with Myc or USF, respectively. The effect of c-Myc and
N-Myc on activity of the -90/+71constructwasless thanfor
the -145/+71 construct. USF expression did not enhance
activity of the -90/+71 construct.
To further investigate involvement of the E box
sequence in ICAD promoter activity, a reporter construct
with an E box mutation (CCCGCG) was constructed and
luciferase activity was examined in transfected cells
(Fig. 3b). The E box mutation resulted in marked down-
regulation of reporter gene expression and the reporter
activity expressed from the E-box mutant was little
increased when co-expressed with Myc, suggesting a
functionally important role of the -106/-90 region E box
motif with regard to basal transcriptional activation of the
ICAD promoter. These data indicates that E-box-binding
proteins, especially Myc, actively participate in positive
regulation of the human ICAD promoter.
Myc binds to the ICAD promoter in vivo
To obtain direct evidence of an interaction between Myc and
the ICAD promoter in vivo, we next examined binding of
c-MycandN-Myctothe50-upstreamregionoftheICADgene
within the context of native chromatin in living cells by
chromatin immunoprecipitation. An alignment of the
sequence around putative Myc binding site of human ICAD
promoter and the corresponding part of mouse ICAD
sequence demonstrated conservation of Myc binding
sequence in human and mouse (Fig. 4a) [16]. Proteins were
cross-linked to genomic DNA isolated not only from human
(Huh-7) but mouse (IMR-32 and GOTO) cells, followed by
immunoprecipitation with normal rabbit IgG or polyclonal
antibodiestoeitherc-MycorN-Myc.IMR-32andGOTOare
neuroblastomacellswithN-Mycgeneampliﬁcation[28].The
precipitated DNA was then subjected to PCR utilizing
primers designed to amplify a 343-bp fragment (-272/+71)
or a 338 bp fragment (-789/-451) of the ICAD 50 ﬂanking
region. As shown in Fig. 4b, the 343-bp DNA fragment was
observed in the immunoprecipitate from Huh-7 cells fol-
lowing exposure to anti-c-Myc or anti-N-Myc, while
ampliﬁcation of the ICAD promoter fragment was not
detected in the negative control immunoprecipitate. Under
similarexperimentalconditions,wedidnotdetectbindingof
c-Myc and N-Myc to the -789/-451 region, which is not
thought to contain a Myc-binding site. Similar results were
GL3basic
Luc(-90/+7
Luc(-145/+
c-Myc
N-Myc
GL3basic
Luc(-90/+71)
Luc(-145/+71)
USF-1
USF-2
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RLU (%)
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A
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B
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-C   --C   -
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Luc(-106/+7
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1)mt
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LUC pLuc(-106/+71)
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RLU (%)
Fig. 3 (a) ICAD promoter activity after transient expression of
c-Myc, N-Myc, USF1 and USF2. Huh-7 cells were cotransfected with
either expression vector for c-Myc, N-Myc, USF1 or USF2 driven by
the CMV promoter and pLuc(-145/+71), pLuc(-90/+71) or pGL3
basic. Each ﬁreﬂy luciferase reporter plasmid (n = 4) was cotrans-
fected in cells with pRL-TK for normalization of the reporter activity.
RLU is expressed as a percentage of that of pLuc(-145/+71) in the
absence of expressing plasmids for Myc and USF. (b) Effect of
substitution mutation in the E-box element on the ICAD promoter
activity. Cells were cotransfected with pLuc(-106/±71) or an E-box-
mutant, pLuc(-106/±71)mt and either expression vector for c-Myc
or N-Myc. pRL-TK was also used for normalization of the activity.
RLU is expressed as a percentage of that of pLuc(-106/±71) without
over-expression of Myc
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123obtained from IMR-32 and GOTO cells, which were immu-
noprecipitated with anti-N-Myc antibody. These results
demonstratethatMycformsacomplexwiththehumanICAD
promoter in cells, presumably through binding to the E-box
sequence.
Myc-dependent expression of the ICAD protein
TheabovedatasuggeststhattheICADpromoterisregulated
by endogenous Myc proteins. This assumption is supported
by the loss-of-function studies shown in Fig. 5a. We
employed siRNA (small interference RNA) transfection to
knock-downtheexpressionofc-MycorN-Mycincells,after
which we analyzed the effect of reduced Myc expression on
steady state levels of the ICAD protein by Western blotting.
Treatment with siRNA speciﬁc for either c-Myc or N-Myc
markedly reduced ICAD expression without affecting the
expression of b-actin. In contrast, control siRNA did not
reduce ICAD levels. We further investigated the effect of
over-expression of Myc on ICAD protein levels (Fig. 5b).
Transfection of Huh-7 and mouse 3T3 cells with a c-Myc
or N-Myc expression vector enhanced ICAD protein
levels with an effect that was less pronounced than in the
A
human   -101 CGCCACACGTGATTAGCGGCAACTAGAACT -72
mouse        GAACGCCCGTGATTAGCCGCCACTAGAACT
Myc/USF GATA-1 HSF
B nt - 272 / + 71
Input N-Myc IgG Input N-Myc IgG
Input c-Myc IgG
nt - 789 / - 451
Input c-Myc IgG
Huh-7
IMR-32
Input N-Myc IgG
nt - 272 / + 71
Input N-Myc IgG
nt - 789 / - 451
GOTO
Input N-Myc IgG
nt - 272 / + 71 nt - 789 / - 451
Input N-Myc IgG
Fig. 4 (a) An alignment of the sequence around putative Myc
binding site of human ICAD promoter and the corresponding part of
mouse ICAD sequence. (b) Binding of Myc proteins in the
endogenous ICAD promoter. Crosslinked chromatins isolated from
Huh-7, IMR-32 and GOTO cells were immunoprecipitated with
indicated antibodies (c-Myc, N-Myc) or an equivalent amount of
mouse IgG. Recovered DNAs were puriﬁed and PCR-ampliﬁed with
primers for nt -272/±71 region or for nt -789/-451 region. Input
represents 1% of chromatin sample applied for immunoprecipitation
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Fig. 5 Myc-dependent expression of human ICAD. (a) Suppression
of Myc expression decreases expression of ICAD protein. Huh-7 cells
were transiently transfected with Myc siRNA (c-Myc, N-Myc) or the
control siRNA (cont). Three days later, the cells were harvested and
subjected to Western blotting. (b) Ectopic expression of Myc
increases expression of ICAD protein. Cells (Huh-7 and mouse
3T3) were transfected with the expression vector for c-Myc or
N-Myc, and after 3 days the cells were harvested for Western
blotting. (c) Comparison of the mRNA expression of c-Myc and ICAD
in Huh-7 cells and human oral squamous carcinoma cells (Ca22-9,
HSC-2, and HSC-3). Levels of mRNA expression of ICAD and
c-Myc were measured by quantitative real-time RT-PCR based on
Taq Man chemistry. Results, relative to b-actin mRNA, are depicted
as averages with SD (n = 3)
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123loss-of-functionstudies,butreproduciblenonetheless.These
results suggest an important role of Myc proteins in positive
regulation of ICAD expression.
Finally, we examined if there might be a correlation
betweenICADandMycexpressionlevelsincancercelllines.
The mRNA expression of ICAD and c-Myc in human oral
squamous cell carcinomas (Ca22-9, HSC-2, and HSC-3), in
which ICAD expression has not been investigated to date, as
well as in Huh-7 cells during their late exponential phase of
growth, was analyzed by quantitative RT-PCR (Fig. 5c).
ICAD mRNA was readily detected in all cancer cells but the
expressionlevelwasnotconsistent.Arelativelyhighlevelof
expression was observed in Ca22-9 and HSC-3 cells, while
HSC-2 cells demonstrated the lowest. Interestingly,
expression pattern of c-Myc mRNA in these cell lines
showed a tendency similar to that of ICAD, suggesting an
importantroleofMycinICADexpressioninhumancancers.
A large scale analysis for investigating correlation between
ICAD and Myc expression in a variety of cancer tissues
obtained from patients is ongoing.
Several studies have shown up- or down-regulation of
ICAD in a variety of human cancers [11–14, 29, 30].
Although transcriptional deregulation is presumably
involved in this aberrant expression of ICAD, little is
known about the transcriptional regulation of ICAD in
human cells. This work was done to characterize the human
ICAD promoter and to examine transcription factors which
may be involved in its regulation. We experimentally
determined putative transcription start sites by employing
the 50-RACE method, and identiﬁed a promoter region
required for basal ICAD gene expression using promoter-
reporter constructs with progressive deletions. A combined
study of site-directed mutagenesis of a reporter construct
and chromatin immunoprecipitation revealed the impor-
tance of an E box Myc-binding motif located at position
-103 to -98 from the transcription start sites, as well as an
in vivo interaction between c-Myc and N-Myc and the
proximal ICAD promoter. Furthermore, we demonstrated
the functional importance of Myc proteins with regard to
transcriptional regulation of the ICAD gene from studies
examining ectopic expression of c-Myc and N-Myc, as well
as with RNAi technology. We showed that expression
levels of ICAD and Myc correlate in some tumors.
c-Myc and N-Myc are transcription factors of the
bHLH LZ family that bind to the E box sequence within
promoters to control proliferation, cell differentiation, and
apoptosis [25, 31, 32]. c-myc and N-myc genes are
deregulated in a number of human cancers and inﬂuence
proliferation and growth. A link between Myc and cancer
is well established both in vivo and in vitro, and onco-
genic activation of Myc has been observed to promote
the development of a number of clinically signiﬁcant
cancers [25, 33]. However, the molecular and cellular
mechanisms of Myc-mediated transformation are not fully
understood. Although a variety of Myc target genes were
identiﬁed and recruitment of Myc to the target promoters
such as prothymosin and telomerase were shown [34],
there has been no direct evidence on involvement of Myc
in regulation of ICAD expression. It is known that c-Myc
activation usually occurs during the later stages of car-
cinoma in humans. Conversely, in premalignant cells,
c-Myc is a robust stimulator of apoptosis and pro-
grammed cell death [32]. One area of investigation into
cancer cell death mechanisms centers on the mechanism
by which c-Myc stimulates or suppresses apoptosis. For
instance, Myc has been reported to potentiate apoptosis
through both p53-dependent and -independent mecha-
nisms [35, 36]. Myc controls the balance between pro-
and anti-apoptotic factors at the level of the mitochondria,
thereby regulating cytochrome C release and activation of
downstream caspases [37, 38]. Involvement of Myc in
up-regulation of ICAD expression as demonstrated in this
study might present a novel mechanism of Myc-depen-
dent inhibition of apoptosis. It is possible that elevated
levels of ICAD in cells inhibit activation of endonuclear
activity, thereby increasing the threshold for apoptosis
signaling.
Kawane et al. have reported on the structure and ana-
lyzed the promoter of a murine ICAD gene, by which they
demonstrated that a 118-bp ﬂanking region of the ICAD
gene is required for its transcription [16]. The mouse
sequence shares approximately 82% homology with a
corresponding upstream region of the human ICAD gene.
The mouse ICAD promoter has a number of potential
binding sites for transcription factors, such as Ikaros, c-Rel,
Myc, and Gﬁ-1 [16]. Conservation of the Myc-binding
motif among human and murine promoters suggests a
functional signiﬁcance of Myc in transcriptional regulation
of ICAD expression.
In conclusion, this is the ﬁrst report to identify a
functional promoter of the human ICAD gene, and to
demonstrate that Myc proteins are able to positively
regulate ICAD gene expression. Extensive apoptosis
research to date has shown that tumor aggression depends
on various defects in apoptosis signaling [39]. Further
investigation into the molecular events linking Myc
expression with ICAD gene regulation may provide
insight into Myc’s role in cell proliferation, transforma-
tion and apoptosis.
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